Background/aims: Signalling via CysLT1 is involved in activation of volume sensitive K(+) channels and homologous desensitization of the LTD4 receptor impairs regulatory volume decrease (RVD). The aim is to illustrate the effect of mutation of putative PKC consensus phosphorylation sites in the CysLT1R on desensitization and RVD.
Methods: mCysLT1 contains 4 putative PKC consensus phosphorylation sites, and four mutants were created: Thr151Gly, Thr323Gly, Thr151Gly plus Thr323Gly, and Thr236Gly plus Ser243Gly. Functional mCysLT1 receptor activity after injection of in vitro transcribed cRNA into Xenopus laevis oocytes was visualized as a LTD4-evoked, Ca(2+)-activated Cl(-) currents recorded by two-electrode voltage clamp.
Results: Repetitive LTD4 administration (100 nM) desensitized the LTD4-evoked currents in oocytes expressing wild type CysLT1. Single mutations as well as the double mutation Thr236Gly plus Ser243Gly had no or a slight effect on the LTD4 induced desensitization. However, double mutation Thr323Gly plus Thr151Gly prevented the desensitization. As a functional consequence we find that inhibition of PKC accelerates RVD and prevents the inhibitory effect of LTD4-pretreatment on RVD in Ehrlich ascites tumour cells.
Conclusion: These data indicate that simultaneous PKC-mediated phosphorylation at the 2(nd) inner loop (Thr(151)) and at the C-terminal domain (Thr(323)) leads to mCysLT1 receptor desensitization and abrogates the RVD response following osmotic cell swelling.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000343374 | DOI Listing |
Alzheimers Dement
December 2024
University of Newcastle, Callaghan, NSW, Australia.
Background: UK Biobank data show mutations related to the iron disorder hemochromatosis can approximately double the risk of dementia, in particular clinically diagnosed vascular dementia. Insights into the etiology of this dementia may be provided by cerebrovasculopathy in our new "Aβ+Iron" mouse model, which combines hemochromatosis-related mutations and amyloidosis, with increases in soluble Aβ species and plaques. This was created by crossing an established APP/PS1 model of β-amyloidosis with our reported HfexTfr2 model of hemochromatosis-related mutations exhibiting brain iron dyshomeostasis (Heidari Mol.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Harvard Medical School, Boston, MA, USA.
Background: Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with repetitive head impact (RHI) although little is known about its molecular pathogenesis. Previous studies of single neurons showed that private somatic mutations increase both during normal aging and in neurodegenerative disorders, and show diverse mutational patterns.
Method: We applied two orthogonal single-nucleus whole-genome sequencing (snWGS) methods to neurons isolated from the prefrontal cortex of 15 individuals with CTE, and 4 individuals with RHI but no CTE diagnosis, and compared mutational rates and spectra with neurons from neurotypical controls and Alzheimer's disease (AD).
Alzheimers Dement
December 2024
Centre for Brain Research, Indian Institute of Science, Bengaluru, Karnataka, India.
Background: Vascular pathology is often seen in cases of mixed dementia affecting elderly population including Alzheimer's disease (AD). AD is generally characterized by the presence of amyloid-β (Aβ) plaques and tau deposits. However, many factors influence the onset and progression of AD pathology.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Indiana University School of Medicine, Indianapolis, IN, USA.
Background: Alzheimer's disease (AD) is the most common form of dementia, yet the effectiveness of disease-modifying interventions is inconclusive. Although exceptional progress in our understanding of AD neuropathology has been made via transgenic mouse models bearing familial mutations, they often fail to recapitulate the disease progression of late-onset AD (LOAD). To address this, MODEL-AD has developed LOAD1 and LOAD2 mouse models which carry the most common human-relevant risk factors for AD.
View Article and Find Full Text PDFCancer
January 2025
Department of Lymphoma, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Background: Double-expressor lymphoma (DEL) has a poorer prognosis than other subtypes of diffuse large B-cell lymphoma (DLBCL). This study is a multicenter, prospective, single-arm, phase 2 clinical study initiated by investigators to evaluate the efficacy and safety of combined zanubrutinib with R-CHOP, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone for patients with DEL (stage II or more), as well as to explore factors related to efficacy preliminarily.
Methods: From November 2020 to July 2022, 48 newly diagnosed patients were enrolled.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!